S&P ASX All Technology

US Dollar vs AUD

Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

Get Started

VIR Vir Biotechnology Inc

7.53

0.13 (1.76%)

28 Dec 2024 - Closed

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/05/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/05/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

/s/ Vanina de Verneuil

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart
From Nov 2024 to Dec 2024

Click Here for more Vir Biotechnology Charts.

Vir Biotechnology (NASDAQ:VIR)
Historical Stock Chart
From Dec 2023 to Dec 2024

Click Here for more Vir Biotechnology Charts.

Vir Biotechnology Inc News

Vir Biotechnology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Thursday 19 December 2024 (1 week ago) • Business Wire

Vir Biotechnology Receives FDA Breakthrough Therapy Designation and EMA PRIME Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta
Friday 13 December 2024 (2 weeks ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Thursday 5 December 2024 (3 weeks ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Tuesday 3 December 2024 (4 weeks ago) • Edgar (US Regulatory)

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs
Wednesday 27 November 2024 (1 month ago) • Business Wire

Vir Biotechnology to Participate in the 7th Annual Evercore ISI HealthCONx Conference
Tuesday 26 November 2024 (1 month ago) • Business Wire

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program
Tuesday 19 November 2024 (1 month ago) • Business Wire

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency
Tuesday 19 November 2024 (1 month ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Tuesday 19 November 2024 (1 month ago) • Edgar (US Regulatory)

Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at AASLD The Liver Meeting
Saturday 16 November 2024 (1 month ago) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Friday 8 November 2024 (2 months ago) • Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities
Thursday 7 November 2024 (2 months ago) • Edgar (US Regulatory)

More Vir Biotechnology Inc News Articles

Xtrackers S&P 500 Swap U...

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions